{
    "AML": {
        "Induction Therapy": {
            "goal": "To achieve complete remission by eradicating visible leukemic blasts and restoring normal hematopoiesis.",
            "protocols": [
                {
                    "protocolName": "3+7 (Daunorubicin/Idarubicin + Cytarabine)",
                    "drugs": [
                        {
                            "day": "Days 1–3",
                            "name": "Daunorubicin or Idarubicin",
                            "dose": "60 mg/m²/day or 2 mg/m²/day ",
                            "route": "IV",
                            "duration": "15–30 min"
                        },
                        {
                            "day": "Days 1–7",
                            "name": "Cytarabine",
                            "dose": "100–200 mg/m²/day",
                            "route": "IV continuous infusion",
                            "duration": "24 hours"
                        }
                    ],
                    "nursingTips": [
                        "Administer anthracycline (Daunorubicin/Idarubicin) only after completion of the previous day's Cytarabine infusion.",
                        "Use central venous line (PICC/CVC) — avoid peripheral veins.",
                        "Start Prednisolone eye drops 2 hours before Cytarabine and continue for 24 hours after last dose.",
                        "Side effects: Nausea and Vomiting"
                    ]
                },
                {
                    "protocolName": "FLAG-IDA (Fludarabine + Cytarabine + G-CSF + Idarubicin)",
                    "drugs": [
                        {
                            "day": "Days 1–5",
                            "name": "Fludarabine",
                            "dose": "30 mg/m²/day",
                            "route": "IV",
                            "duration": "30 min"
                        },
                        {
                            "day": "Days 1–5",
                            "name": "Cytarabine",
                            "dose": "2 g/m²/day",
                            "route": "IV infusion",
                            "duration": "4 hours"
                        },
                        {
                            "day": "Days 1–5",
                            "name": "Filgrastim (G-CSF)",
                            "dose": "5 µg/kg/day",
                            "route": "SC",
                            "duration": "Start 24 h before chemo"
                        },
                        {
                            "day": "Days 1–3",
                            "name": "Idarubicin",
                            "dose": "10 mg/m²/day",
                            "route": "IV",
                            "duration": "30 min"
                        }
                    ],
                    "nursingTips": [
                        "Start G-CSF 24 hours before chemotherapy and continue until neutrophil recovery.",
                        "Use strict aseptic technique — high infection risk during profound cytopenia.",
                        "Monitor for neurotoxicity during high-dose Cytarabine infusion."
                    ]
                },
                {
                    "protocolName": "CLAG-M (Cladribine + Cytarabine + G-CSF + Mitoxantrone)",
                    "drugs": [
                        {
                            "day": "Days 1–5",
                            "name": "Cladribine",
                            "dose": "5 mg/m²/day",
                            "route": "IV infusion",
                            "duration": "1–2 hours"
                        },
                        {
                            "day": "Days 1–5",
                            "name": "Cytarabine",
                            "dose": "2 g/m²/day",
                            "route": "IV infusion",
                            "duration": "4 hours"
                        },
                        {
                            "day": "Days 1–5",
                            "name": "Filgrastim (G-CSF)",
                            "dose": "5 µg/kg/day",
                            "route": "SC",
                            "duration": "Start 24 h before chemo"
                        },
                        {
                            "day": "Days 1–3",
                            "name": "Mitoxantrone",
                            "dose": "10 mg/m²/day",
                            "route": "IV",
                            "duration": "30 min"
                        }
                    ],
                    "nursingTips": [
                        "Ensure adequate hydration and allopurinol for tumor lysis prevention.",
                        "Monitor for cardiac toxicity due to Mitoxantrone.",
                        "Continue G-CSF until post-nadir recovery."
                    ]
                }
            ]
        },
        "Consolidation Therapy": {
            "goal": "To eliminate residual leukemic cells and consolidate remission achieved during induction.",
            "protocols": [
                {
                    "protocolName": "HiDAC (High-Dose Cytarabine)",
                    "drugs": [
                        {
                            "day": "Days 1, 3, 5",
                            "name": "Cytarabine",
                            "dose": "3 g/m² every 12 hours",
                            "route": "IV infusion",
                            "duration": "3 hours"
                        }
                    ],
                    "nursingTips": [
                        "Administer via central line only — high risk of phlebitis with peripheral access.",
                        "Start Prednisolone eye drops before the first Cytarabine dose and continue for 48 hours after the last dose to prevent conjunctivitis.",
                        "Monitor for neurotoxicity (e.g., ataxia, confusion) — perform neuro checks before each dose.",
                        "Ensure adequate hydration and monitor renal function to reduce toxicity."
                    ]
                },
                {
                    "protocolName": "Intermediate-Dose Cytarabine",
                    "drugs": [
                        {
                            "day": "Days 1–5",
                            "name": "Cytarabine",
                            "dose": "1–1.5 g/m² every 12 hours",
                            "route": "IV infusion",
                            "duration": "3 hours"
                        }
                    ],
                    "nursingTips": [
                        "Use central access; avoid peripheral lines for repeated high-dose infusions.",
                        "Implement neuro checks and monitor for cerebellar toxicity throughout treatment.",
                        "Eye drop prophylaxis required for all patients.",
                        "Assess for cumulative myelosuppression — expect delayed neutrophil and platelet recovery."
                    ]
                }
            ]
        },
        "Maintenance Therapy": {
            "goal": "To maintain remission, prolong survival, and delay relapse in patients not undergoing transplant.",
            "protocols": [
                {
                    "protocolName": "Oral Azacitidine (CC-486)",
                    "drugs": [
                        {
                            "day": "Days 1–14 of each 28-day cycle",
                            "name": "Oral Azacitidine (CC-486)",
                            "dose": "300 mg orally once daily",
                            "route": "PO",
                            "duration": "With or without food"
                        }
                    ],
                    "nursingTips": [
                        "Nausea, vomiting, and diarrhea are common. Provide antiemetics as needed."
                    ]
                },
                {
                    "protocolName": "Low-Dose Cytarabine Maintenance",
                    "drugs": [
                        {
                            "day": "Twice weekly (e.g., Mon/Thu)",
                            "name": "Cytarabine",
                            "dose": "20 mg/m²",
                            "route": "SC",
                            "duration": "Single daily injection"
                        }
                    ],
                    "nursingTips": [
                        "Provide patient/caregiver injection training or schedule in outpatient unit.",
                        "Monitor for injection site reactions or bruising.",
                        "Schedule regular CBCs and renal/liver monitoring during treatment.",
                        "Continue until toxicity, relapse, or loss of response."
                    ]
                }
            ]
        },
        "Post-Maintenance Surveillance": {
            "goal": "To detect relapse early, manage long-term toxicities, and support recovery and quality of life in patients after completing therapy.",
            "protocols": [
                {
                    "protocolName": "Routine Monitoring",
                    "drugs": [],
                    "nursingTips": [
                        "Schedule CBC every 1–3 months for the first 2 years, then space to every 3–6 months.",
                        "Perform bone marrow biopsy if abnormal counts or symptoms suggest relapse.",
                        "Use MRD testing if available to detect molecular relapse early."
                    ]
                },
                {
                    "protocolName": "Supportive Care",
                    "drugs": [],
                    "nursingTips": [
                        "Administer yearly influenza vaccine and pneumococcal revaccination every 5 years.",
                        "Monitor cardiac and renal function every 6–12 months, especially if prior anthracyclines were used.",
                        "Assess for fatigue, mental health, and overall quality of life regularly.",
                        "Offer fertility and nutritional counseling where relevant."
                    ]
                },
                {
                    "protocolName": "Relapse Planning",
                    "drugs": [],
                    "nursingTips": [
                        "For MRD-positive or clinical relapse, evaluate for salvage options such as Venetoclax + Azacitidine or FLAG-IDA.",
                        "Refer transplant-eligible patients promptly to transplant team.",
                        "Consider palliative or low-intensity regimens for those unfit for intensive therapy."
                    ]
                }
            ]
        },
        "Salvage Therapy": {
            "goal": "To reinduce remission in patients with relapsed or refractory AML and offer bridge to transplant when eligible.",
            "protocols": [
                {
                    "protocolName": "FLAG-IDA (Fludarabine + Cytarabine + G-CSF + Idarubicin)",
                    "drugs": [
                        {
                            "day": "Days 1–5",
                            "name": "Fludarabine",
                            "dose": "30 mg/m²/day",
                            "route": "IV",
                            "duration": "30 min"
                        },
                        {
                            "day": "Days 1–5",
                            "name": "Cytarabine",
                            "dose": "2 g/m²/day",
                            "route": "IV infusion",
                            "duration": "4 hours"
                        },
                        {
                            "day": "Days 1–5",
                            "name": "Filgrastim (G-CSF)",
                            "dose": "5 µg/kg/day",
                            "route": "SC",
                            "duration": "Start 24 h before chemo"
                        },
                        {
                            "day": "Days 1–3",
                            "name": "Idarubicin",
                            "dose": "10 mg/m²/day",
                            "route": "IV",
                            "duration": "30 min"
                        }
                    ],
                    "nursingTips": [
                        "Ensure strict infection prevention — high neutropenic risk.",
                        "Hydration and tumor lysis prophylaxis (e.g., allopurinol) required.",
                        "Monitor cardiac function due to cumulative anthracycline exposure."
                    ]
                },
                {
                    "protocolName": "Venetoclax + Azacitidine",
                    "drugs": [
                        {
                            "day": "Days 1–28",
                            "name": "Venetoclax",
                            "dose": "400 mg daily",
                            "route": "PO",
                            "duration": "Daily with ramp-up"
                        },
                        {
                            "day": "Days 1–7",
                            "name": "Azacitidine",
                            "dose": "75 mg/m²/day",
                            "route": "SC or IV",
                            "duration": "Once daily"
                        }
                    ],
                    "nursingTips": [
                        "Start with dose ramp-up for Venetoclax to avoid tumor lysis.",
                        "Monitor for cytopenias and infections — antifungal prophylaxis advised.",
                        "Used especially in older/unfit patients or those with IDH mutations."
                    ]
                },
                {
                    "protocolName": "CPX-351 (Liposomal Daunorubicin + Cytarabine)",
                    "drugs": [
                        {
                            "day": "Days 1, 3, 5",
                            "name": "CPX-351 (Vyxeos)",
                            "dose": "44 mg/m² daunorubicin + 100 mg/m² cytarabine",
                            "route": "IV infusion",
                            "duration": "90 minutes"
                        }
                    ],
                    "nursingTips": [
                        "Indicated for therapy-related AML or AML with MDS-related changes.",
                        "Monitor for delayed count recovery — expect prolonged neutropenia.",
                        "Administer via central line; premedicate to prevent infusion reactions."
                    ]
                }
            ]
        }
    },

    "ALL": {
        "Induction Therapy": {
            "goal": "To achieve complete remission with age- and subtype-appropriate regimens.",
            "protocols": [
                {
                    "protocolName": "Ph+ ALL – Ponatinib + Blinatumomab",
                    "drugs": [
                        { "day": "Cycle 1–2", "name": "Ponatinib", "dose": "30 mg daily", "route": "Oral", "duration": "Continuous" },
                        { "day": "Cycle 1–2", "name": "Blinatumomab", "dose": "9 mcg/day → 28 mcg/day", "route": "IV", "duration": "28 days continuous infusion" }
                    ],
                    "nursingTips": [
                        "Monitor for cytokine release and neurotoxicity; ensure dedicated IV line for Blinatumomab."
                    ]
                },
                {
                    "protocolName": "Ph– ALL (14–50 yrs) – R-BFM + Blinatumomab",
                    "drugs": [
                        { "day": "1–33", "name": "BFM protocol drugs", "dose": "Per schedule", "route": "Various", "duration": "33 days" },
                        { "day": "Post induction", "name": "Blinatumomab", "dose": "As per MRD status", "route": "IV", "duration": "28 days" }
                    ],
                    "nursingTips": [
                        "Ensure adherence to schedule; monitor LFTs and blood counts."
                    ]
                }
            ]
        },

        "Consolidation Therapy": {
            "goal": "To eliminate residual disease after induction. Uses HyperCVAD A & B alternate 8 cycles every 28 days",
            "protocols": [
                {
                    "protocolName": "HyperCVAD Cycle A",
                    "drugs": [
                        {
                            "day": "Day 1-3",
                            "name": "Cyclophosphamide",
                            "dose": "300 mg/m² every 12 hours × 6 doses",
                            "route": "IV",
                            "duration": "Over 3 hours"
                        },
                        {
                            "day": "Day 1–3",
                            "name": "Mesna",
                            "dose": "600 mg/m²/day (divided doses)",
                            "route": "IV/PO",
                            "duration": "Given with cyclophosphamide"
                        },
                        {
                            "day": "Day 1-4",
                            "name": "Dexamethasone",
                            "dose": "40 mg",
                            "route": "PO/IV",
                            "duration": "4 Days"
                        },
                        {
                            "day": "Day 4",
                            "name": "Doxorubicin",
                            "dose": "50 mg/m²",
                            "route": "IV",
                            "duration": "Over 4 hours"
                        },
                        {
                            "day": "Day 4",
                            "name": "Vincristine",
                            "dose": "2 mg",
                            "route": "IV",
                            "duration": "Push"
                        },
                        {
                            "day": "Day 11-14",
                            "name": "Dexamethasone",
                            "dose": "40 mg",
                            "route": "PO/IV",
                            "duration": "4 Days"
                        },
                        {
                            "day": "Day 11",
                            "name": "Vincristine",
                            "dose": "2 mg",
                            "route": "IV",
                            "duration": "Push"
                        }
                    ],
                    "nursingTips": [
                        "Monitor for hemorrhagic cystitis; ensure adequate Mesna coverage.",
                        "Strict fluid intake/output monitoring during Cyclophosphamide.",
                        "BM before Vincristine, check for constipation, neuropathy",
                        "Check cardiac function before Doxorubicin; watch for infusion reactions."
                    ]
                },
                {
                    "protocolName": "HyperCVAD Cycle B",
                    "drugs": [
                        {
                            "day": "Day 1",
                            "name": "Methotrexate (High Dose)",
                            "dose": "1 g/m²",
                            "route": "IV",
                            "duration": "Over 24 hours"
                        },
                        {
                            "day": "Day 1-3",
                            "name": "Methylprednisolone",
                            "dose": "50 mg every 12 hours",
                            "route": "IV",
                            "duration": "3 Days"
                        },
                        {
                            "day": "Day 2 (36 hours after start of MTX)",
                            "name": "Leucovorin Rescue",
                            "dose": "15 mg every 6 hours",
                            "route": "IV/PO",
                            "duration": "Until methotrexate level <0.1"
                        },
                        {
                            "day": "Day 2-3",
                            "name": "Cytarabine",
                            "dose": "3 g/m² every 12 hours × 4 doses",
                            "route": "IV",
                            "duration": "Over 3 hours"
                        }
                    ],
                    "nursingTips": [
                        "Check urine pH daily and maintain pH > 8 during high-dose Methotrexate.",
                        "MTX level daily 24 hours after MTX started",
                        "Monitor for Cytarabine",
                        "Ensure steroid-induced hyperglycemia monitoring.",
                        "Eye-drop prophylaxis required for high-dose Cytarabine (Prednisolone drops)."
                    ]
                }

            ]
        },
 
        "Maintenance Therapy": {
            "goal": "To maintain remission and prevent relapse.",
            "protocols": [
                {
                    "protocolName": "POMP Regimen",
                    "drugs": [
                        { "day": "Daily", "name": "6-Mercaptopurine", "dose": "50–75 mg/m²", "route": "Oral", "duration": "2 years" },
                        { "day": "Weekly", "name": "Methotrexate", "dose": "20 mg/m²", "route": "Oral", "duration": "2 years" },
                        { "day": "Monthly", "name": "Vincristine", "dose": "1.4 mg/m²", "route": "IV", "duration": "Monthly" },
                        { "day": "Monthly", "name": "Prednisone", "dose": "40 mg/m²", "route": "Oral", "duration": "5 days each cycle" }
                    ],
                    "nursingTips": [
                        "Monitor CBC, LFTs, and infection signs; encourage adherence to oral meds."
                    ]
                
                }
            ]
        },

        "CNS Prophylaxis": {
            "goal": "To prevent central nervous system relapse.",
            "protocols": [
                {
                    "protocolName": "Intrathecal Therapy",
                    "drugs": [
                        { "day": "Scheduled", "name": "Methotrexate ± Cytarabine ± Hydrocortisone", "dose": "Per center protocol", "route": "Intrathecal", "duration": "As scheduled" }
                    ],
                    "nursingTips": [
                        "Ensure proper patient positioning post-procedure; monitor for headache or nausea."
                    ]
                }
            ]
        },

        "Salvage / Relapse Therapy": {
            "goal": "To achieve remission in relapsed or refractory cases.",
            "protocols": [
                {
                    "protocolName": "Blinatumomab / Inotuzumab / CAR-T",
                    "drugs": [
                        { "name": "Blinatumomab", "dose": "As per MRD status", "route": "IV", "duration": "Continuous 28 days" },
                        { "name": "Inotuzumab ozogamicin", "dose": "0.8 mg/m² → 0.5 mg/m²", "route": "IV", "duration": "Cycle-based" }
                    ],
                    "nursingTips": [
                        "Monitor for cytokine release and veno-occlusive disease; consider transplant if eligible."
                    ]
                }
            ]
        }
    },

    "CML": {
        "Chronic Phase": {
            "goal": "To suppress BCR-ABL activity, prevent progression, and maintain long-term remission.",
            "protocols": [
                {
                    "protocolName": "Imatinib (First-Line TKI)",
                    "drugs": [
                      {
                        "day": "Daily",
                        "name": "Imatinib",
                        "dose": "400 mg once daily",
                        "route": "Oral",
                        "duration": "Continuous"
                      }
                    ],
                    "nursingTips": [
                        "Monitor CBC and liver enzymes every 2–4 weeks initially.",
                        "Assess adherence — missed doses can lead to resistance.",
                        "Take with food and a full glass of water to reduce GI upset."
                    ]
                },
                {
                  "protocolName": "Dasatinib",
                  "drugs": [
                      {
                          "day": "Daily",
                          "name": "Dasatinib",
                          "dose": "100 mg once daily",
                          "route": "Oral",
                          "duration": "Continuous"
                      }
                  ],
                  "nursingTips": [
                    "Monitor for pleural effusion — report dyspnea or cough.",
                    "Avoid concurrent PPIs (reduces absorption).",
                    "Frequent CBC checks due to potential cytopenias."
                  ]
                },
                {
                    "protocolName": "Nilotinib",
                    "drugs": [
                        {
                            "day": "Every 12 hours",
                            "name": "Nilotinib",
                            "dose": "300 mg twice daily",
                            "route": "Oral",
                            "duration": "Continuous"
                        }
                    ],
                    "nursingTips": [
                        "Give on an empty stomach (avoid food 2 hours before and 1 hour after).",
                        "Monitor ECG for QT prolongation.",
                        "Frequent monitoring of glucose and lipids."
                    ]
                }
            ]
        },

        "Accelerated Phase": {
          "goal": "To regain hematologic control and prevent transition to blast crisis.",
          "protocols": [
            {
              "protocolName": "High-Dose Imatinib",
              "drugs": [
                {
                  "day": "Daily",
                  "name": "Imatinib",
                  "dose": "600–800 mg daily",
                  "route": "Oral",
                  "duration": "Continuous"
                }
              ],
              "nursingTips": [
                "Increased GI and edema risk at higher doses.",
                "Monitor BCR-ABL transcript levels every 3 months."
              ]
            },
            {
              "protocolName": "Second-Generation TKI (Dasatinib/Nilotinib)",
              "drugs": [
                {
                  "day": "Daily",
                  "name": "Dasatinib or Nilotinib",
                  "dose": "Per guideline",
                  "route": "Oral",
                  "duration": "Continuous"
                }
              ],
              "nursingTips": [
                "Used when resistance or intolerance to Imatinib occurs.",
                "Monitor for severe myelosuppression."
              ]
            }
          ]
        },

        "Blast Crisis": {
          "goal": "To rapidly control blast proliferation and prepare for transplant when possible.",
          "protocols": [
            {
              "protocolName": "Third-Generation TKI (Ponatinib)",
              "drugs": [
                {
                  "day": "Daily",
                  "name": "Ponatinib",
                  "dose": "15–45 mg daily (mutation-dependent)",
                  "route": "Oral",
                  "duration": "Continuous"
                }
              ],
              "nursingTips": [
                "Effective against T315I mutation.",
                "Monitor for hypertension and vascular events.",
                "Frequent CBC and liver function monitoring required."
              ]
            },

            {
              "protocolName": "HyperCVAD A",
              "drugs": [
                { "day": "Days 1–3", "name": "Cyclophosphamide", "dose": "300 mg/m² every 12 hours", "route": "IV", "duration": "6 doses" },
                { "day": "Day 1–3", "name": "Mesna", "dose": "Per protocol", "route": "IV", "duration": "Uroprotection" },
                { "day": "Day 4 & 11", "name": "Vincristine", "dose": "2 mg", "route": "IV", "duration": "Rapid push" },
                { "day": "Day 4", "name": "Doxorubicin (Adriamycin)", "dose": "50 mg/m²", "route": "IV", "duration": "Administer slowly" },
                { "day": "Days 1–4 & 11–14", "name": "Dexamethasone", "dose": "40 mg/day", "route": "Oral/IV", "duration": "Steroid backbone" }
              ],
              "nursingTips": [
                "Hyperhydration and Mesna are mandatory to prevent hemorrhagic cystitis.",
                "Monitor for neurotoxicity with vincristine.",
                "Track cardiac function due to anthracycline exposure.",
                "Monitor glucose during steroid pulses."
              ]
            },

            {
              "protocolName": "HyperCVAD B",
              "drugs": [
                { "day": "Day 1", "name": "Methotrexate", "dose": "1 g/m²", "route": "IV", "duration": "Over several hours" },
                { "day": "Day 2", "name": "Cytarabine", "dose": "3 g/m² every 12 hours × 2 doses", "route": "IV", "duration": "High-dose" },
                { "day": "Multiple Days", "name": "Leucovorin Rescue", "dose": "Per protocol", "route": "IV/Oral", "duration": "Begin 24 hours post-MTX" }
              ],
              "nursingTips": [
                "Strict hydration and urine alkalinization required for MTX safety.",
                "Monitor for cerebellar toxicity with high-dose Cytarabine.",
                "Daily lab monitoring: renal function, MTX levels.",
                "Eye drop prophylaxis for Cytarabine."
              ]
            }
          ]
        }
    },

    "CLL": {
        "Frontline Therapy": {
            "goal": "To control disease, achieve deep remissions, and minimize treatment toxicity using targeted or chemo-immunotherapy regimens.",
            "protocols": [
                {
                    "protocolName": "Venetoclax + Obinutuzumab (Modern First-Line)",
                    "drugs": [
                        { "day": "Cycle 1 (Day 1, 2, 8, 15)", "name": "Obinutuzumab", "dose": "100 mg → 900 mg → 1000 mg", "route": "IV", "duration": "Per infusion protocol" },
                        { "day": "Cycle 1–6", "name": "Venetoclax", "dose": "20 → 50 → 100 → 200 → 400 mg ramp-up", "route": "PO", "duration": "Daily after ramp-up" }
                    ],
                    "nursingTips": [
                        "TLS risk highest during Venetoclax ramp-up; ensure hydration and monitoring.",
                        "Premedicate before Obinutuzumab to avoid infusion reactions.",
                        "Monitor lymphocyte count and tumor burden closely."
                    ]
                },
                {
                    "protocolName": "Acalabrutinib (BTK Inhibitor)",
                    "drugs": [
                        { "day": "Continuous", "name": "Acalabrutinib", "dose": "100 mg twice daily", "route": "PO", "duration": "Continuous" }
                    ],
                    "nursingTips": [
                        "Lower bleeding risk than ibrutinib but still significant; assess platelet inhibitors.",
                        "Avoid PPIs — reduces Acalabrutinib absorption.",
                        "Monitor for headaches; usually improves with caffeine or simple analgesics."
                    ]
                },
                {
                    "protocolName": "Zanubrutinib",
                    "drugs": [
                        { "day": "Continuous", "name": "Zanubrutinib", "dose": "160 mg twice daily or 320 mg daily", "route": "PO", "duration": "Continuous" }
                    ],
                    "nursingTips": [
                        "Monitor BP and heart rhythm; BTK inhibitors increase AF risk.",
                        "Check for bruising or minor bleeding.",
                        "Preferred over ibrutinib due to better tolerability."
                    ]
                },
                {
                    "protocolName": "Ibrutinib (Older BTKi)",
                    "drugs": [
                        { "day": "Continuous", "name": "Ibrutinib", "dose": "420 mg daily", "route": "PO", "duration": "Continuous" }
                    ],
                    "nursingTips": [
                        "Higher cardiac toxicity than newer BTKi; monitor for palpitations.",
                        "Watch for bruising, diarrhea, muscle cramps.",
                        "Avoid strong CYP3A inhibitors."
                    ]
                },
                {
                    "protocolName": "FCR (Fludarabine + Cyclophosphamide + Rituximab) — Classic",
                    "drugs": [
                        { "day": "Days 1–3", "name": "Fludarabine", "dose": "25 mg/m²", "route": "IV", "duration": "Per protocol" },
                        { "day": "Days 1–3", "name": "Cyclophosphamide", "dose": "250 mg/m²", "route": "IV", "duration": "Per protocol" },
                        { "day": "Day 1", "name": "Rituximab", "dose": "375 mg/m² first cycle → 500 mg/m²", "route": "IV", "duration": "Premedicate required" }
                    ],
                    "nursingTips": [
                        "High immunosuppression risk — infection prophylaxis necessary.",
                        "Requires antiviral + PJP prophylaxis.",
                        "Monitor for hemolysis in del(17p) or TP53 mutation (FCR not recommended)."
                    ]
                },
                {
                    "protocolName": "BR (Bendamustine + Rituximab) — Classic",
                    "drugs": [
                        { "day": "Days 1–2", "name": "Bendamustine", "dose": "90 mg/m²", "route": "IV", "duration": "Per protocol" },
                        { "day": "Day 1", "name": "Rituximab", "dose": "375–500 mg/m²", "route": "IV", "duration": "Premedicate required" }
                    ],
                    "nursingTips": [
                        "Better tolerated than FCR for older adults.",
                        "Expect cytopenias after cycle 2–3; monitor CBC closely.",
                        "Give antiviral and PJP prophylaxis."
                    ]
                }
            ]
        },

        "Relapsed/Refractory Therapy": {
            "goal": "To achieve durable remission in patients who relapse after first-line treatment or have high-risk genetic profiles.",
            "protocols": [
                {
                    "protocolName": "Venetoclax + Rituximab (Modern R/R)",
                    "drugs": [
                        { "day": "Cycle 1–6", "name": "Venetoclax", "dose": "20 → 400 mg ramp-up", "route": "PO", "duration": "Daily" },
                        { "day": "Cycle 1–6", "name": "Rituximab", "dose": "375 mg/m² → 500 mg/m²", "route": "IV", "duration": "Per schedule" }
                    ],
                    "nursingTips": [
                        "Highest TLS risk occurs at treatment initiation.",
                        "Needs tumor lysis prophylaxis and lab checks.",
                        "Monitor neutropenia — common with Venetoclax."
                    ]
                },
                {
                    "protocolName": "Acalabrutinib (BTKi)",
                    "drugs": [
                        { "day": "Continuous", "name": "Acalabrutinib", "dose": "100 mg BID", "route": "PO", "duration": "Continuous" }
                    ],
                    "nursingTips": [
                        "Preferred for patients intolerant to ibrutinib.",
                        "Monitor for headaches, AFib, bleeding.",
                        "Avoid PPIs."
                    ]
                },
                {
                    "protocolName": "Pirtobrutinib (Next-Gen BTKi)",
                    "drugs": [
                        { "day": "Continuous", "name": "Pirtobrutinib", "dose": "200 mg daily", "route": "PO", "duration": "Continuous" }
                    ],
                    "nursingTips": [
                        "Useful even after failure of other BTK inhibitors.",
                        "Generally well tolerated; monitor for infections.",
                        "Check for bleeding/bruising."
                    ]
                },
                {
                    "protocolName": "High-Dose Steroids + Rituximab (Classic R/R)",
                    "drugs": [
                        { "day": "Days 1–3", "name": "Methylprednisolone", "dose": "1 g/day", "route": "IV", "duration": "3 days" },
                        { "day": "Day 1", "name": "Rituximab", "dose": "375 mg/m²", "route": "IV", "duration": "Premedicate" }
                    ],
                    "nursingTips": [
                        "Used for refractory CLL or auto-immune cytopenias.",
                        "High hyperglycemia risk — monitor sugars.",
                        "Monitor for infusion reactions."
                    ]
                }
            ]
        },

        "Supportive Care": {
            "goal": "To manage complications associated with CLL and its treatments.",
            "protocols": [
                {
                    "protocolName": "Infection Prophylaxis",
                    "drugs": [],
                    "nursingTips": [
                        "Give antiviral prophylaxis during anti-CD20 or FCR/BR therapy.",
                        "Provide PJP prophylaxis with fludarabine-based regimens.",
                        "Vaccinate (influenza, COVID, pneumococcal) — avoid live vaccines."
                    ]
                },
                {
                    "protocolName": "Hypogammaglobulinemia Management",
                    "drugs": [
                        { "day": "Monthly", "name": "IVIG", "dose": "0.3–0.5 g/kg", "route": "IV", "duration": "Slow infusion" }
                    ],
                    "nursingTips": [
                        "Indicated for recurrent bacterial infections.",
                        "Monitor for allergic reactions or headache."
                    ]
                },
                {
                    "protocolName": "Tumor Lysis Syndrome Prevention",
                    "drugs": [
                        { "day": "Per protocol", "name": "Allopurinol", "dose": "100–300 mg/day", "route": "PO", "duration": "Start 2–3 days prior" },
                        { "day": "High-risk cases", "name": "Rasburicase", "dose": "6 mg single dose", "route": "IV", "duration": "One-time" }
                    ],
                    "nursingTips": [
                        "TLS risk highest with Venetoclax initiation.",
                        "Ensure aggressive hydration and serial labs.",
                        "Monitor potassium, uric acid, phosphate closely."
                    ]
                }
            ]
        }
    },

    "APL": {
        "Induction Therapy": {
            "goal": "To achieve remission by rapidly reducing leukemic promyelocytes using differentiation therapy.",
            "protocols": [
                {
                    "protocolName": "ATRA + ATO (Standard-Risk APL)",
                    "drugs": [
                        { "day": "Day 1–Induction complete", "name": "ATRA (Tretinoin)", "dose": "45 mg/m²/day divided BID", "route": "Oral", "duration": "Daily" },
                        { "day": "Days 1–42", "name": "Arsenic Trioxide (ATO)", "dose": "0.15 mg/kg/day", "route": "IV", "duration": "Daily infusion" }
                    ],
                    "nursingTips": [
                        "Monitor QTc closely — correct low potassium and magnesium before ATO.",
                        "Watch for differentiation syndrome (fever, dyspnea, weight gain) — start steroids immediately.",
                        "Ensure central line access for repeated ATO infusions."
                    ]
                },
                {
                    "protocolName": "ATRA + Anthracycline (High-Risk APL)",
                    "drugs": [
                        { "day": "Day 1–Induction complete", "name": "ATRA (Tretinoin)", "dose": "45 mg/m²/day divided BID", "route": "Oral", "duration": "Daily" },
                        { "day": "Day 1", "name": "Idarubicin", "dose": "12 mg/m²", "route": "IV", "duration": "Single dose or per protocol" },
                        { "day": "Additional", "name": "ATO (optional)", "dose": "0.15 mg/kg/day", "route": "IV", "duration": "Center-specific" }
                    ],
                    "nursingTips": [
                        "High-risk APL = WBC > 10 × 10⁹/L — requires anthracycline support.",
                        "Monitor for coagulopathy — APL patients have DIC risk.",
                        "Check cardiac function when using anthracyclines."
                    ]
                }
            ]
        },

        "Consolidation Therapy": {
            "goal": "To deepen remission and eliminate minimal residual disease.",
            "protocols": [
                {
                    "protocolName": "ATRA + ATO Cycles (Standard-Risk)",
                    "drugs": [
                        { "day": "ATRA", "name": "ATRA", "dose": "45 mg/m²/day", "route": "Oral", "duration": "2 weeks on / 2 weeks off" },
                        { "day": "ATO", "name": "Arsenic Trioxide", "dose": "0.15 mg/kg/day", "route": "IV", "duration": "5 days/week × 4 weeks per cycle" }
                    ],
                    "nursingTips": [
                        "QTc monitoring remains critical during consolidation.",
                        "Hydration reduces ATO toxicity.",
                        "Assess LFTs weekly; hold if severe elevation."
                    ]
                },
                {
                    "protocolName": "ATRA + Chemotherapy (High-Risk)",
                    "drugs": [
                        { "day": "Cycle-based", "name": "ATRA", "dose": "45 mg/m²/day", "route": "Oral", "duration": "As per cycle" },
                        { "day": "Cycle-based", "name": "Anthracycline (Idarubicin or Daunorubicin)", "dose": "Per protocol", "route": "IV", "duration": "Per cycle" }
                    ],
                    "nursingTips": [
                        "Monitor cumulative anthracycline exposure.",
                        "Consider ATO addition based on MRD levels.",
                        "Expected cytopenias — monitor CBC regularly."
                    ]
                }
            ]
        },

        "Maintenance Therapy": {
            "goal": "To prevent relapse after achieving molecular remission, especially in high-risk patients.",
            "protocols": [
                {
                    "protocolName": "ATRA + 6-MP + Methotrexate",
                    "drugs": [
                        { "day": "Days 1–14 (every 3 months)", "name": "ATRA", "dose": "45 mg/m²/day", "route": "Oral", "duration": "14-day pulse" },
                        { "day": "Daily", "name": "6-Mercaptopurine", "dose": "50–75 mg/m²/day", "route": "Oral", "duration": "Continuous" },
                        { "day": "Weekly", "name": "Methotrexate", "dose": "15 mg/m²", "route": "Oral", "duration": "Weekly" }
                    ],
                    "nursingTips": [
                        "CBC and LFT monitoring mandatory due to 6-MP and MTX toxicity.",
                        "Educate patient to avoid alcohol with methotrexate.",
                        "Check for mucositis and bone marrow suppression."
                    ]
                }
            ]
        },

        "Supportive Care": {
            "goal": "To manage complications unique to APL, especially coagulopathy and differentiation syndrome.",
            "protocols": [
                {
                    "protocolName": "Coagulopathy Management",
                    "drugs": [
                        { "day": "As needed", "name": "Cryoprecipitate", "dose": "Maintain fibrinogen > 150 mg/dL", "route": "IV", "duration": "Per transfusion" },
                        { "day": "As needed", "name": "Platelets", "dose": "Maintain > 30–50 ×10⁹/L", "route": "IV", "duration": "Per transfusion" }
                    ],
                    "nursingTips": [
                        "APL induction frequently presents with DIC.",
                        "Maintain aggressive transfusion support early in treatment.",
                        "Monitor coagulation profile daily during induction."
                    ]
                },
                {
                    "protocolName": "Differentiation Syndrome Prophylaxis",
                    "drugs": [
                        { "day": "Early sign onset", "name": "Dexamethasone", "dose": "10 mg IV twice daily", "route": "IV", "duration": "Until symptoms resolve" }
                    ],
                    "nursingTips": [
                        "Symptoms: fever, dyspnea, weight gain, edema.",
                        "Start steroids immediately — do NOT wait for confirmatory tests.",
                        "Hold ATRA/ATO temporarily in severe cases."
                    ]
                }
            ]
        }
    },

    "MM": {
        "Induction Therapy": {
            "goal": "To achieve rapid disease control and prepare eligible patients for stem-cell transplantation.",
            "protocols": [
                {
                    "protocolName": "VRd (Bortezomib + Lenalidomide + Dexamethasone)",
                    "drugs": [
                        {
                            "day": "Days 1, 4, 8, 11",
                            "name": "Bortezomib",
                            "dose": "1.3 mg/m²",
                            "route": "SC or IV",
                            "duration": "Bolus"
                        },
                        {
                            "day": "Days 1–14",
                            "name": "Lenalidomide",
                            "dose": "25 mg daily",
                            "route": "PO",
                            "duration": "Daily × 14 days"
                        },
                        {
                            "day": "Days 1, 8, 15",
                            "name": "Dexamethasone",
                            "dose": "40 mg",
                            "route": "PO/IV",
                            "duration": "Weekly"
                        }
                    ],
                    "nursingTips": [
                        "Use SC route for bortezomib to reduce neuropathy risk.",
                        "Monitor CBC; both bortezomib and lenalidomide cause cytopenia.",
                        "Start antiviral prophylaxis (acyclovir) to prevent VZV reactivation."
                    ]
                },
                {
                    "protocolName": "Dara-VRd (Daratumumab + VRd)",
                    "drugs": [
                        {
                            "day": "Weekly during cycles 1–2",
                            "name": "Daratumumab",
                            "dose": "16 mg/kg (IV) or 1,800 mg (SC)",
                            "route": "IV/SC",
                            "duration": "As per infusion protocol"
                        },
                        {
                            "day": "Days 1, 4, 8, 11",
                            "name": "Bortezomib",
                            "dose": "1.3 mg/m²",
                            "route": "SC",
                            "duration": "Bolus"
                        },
                        {
                            "day": "Days 1–14",
                            "name": "Lenalidomide",
                            "dose": "25 mg",
                            "route": "PO",
                            "duration": "Daily"
                        },
                        {
                            "day": "Days 1, 8, 15",
                            "name": "Dexamethasone",
                            "dose": "40 mg",
                            "route": "PO/IV",
                            "duration": "Weekly"
                        }
                    ],
                    "nursingTips": [
                        "Premedicate Daratumumab: steroid, antihistamine, antipyretic.",
                        "Monitor closely for infusion-related reactions during first dose.",
                        "Ensure antiviral prophylaxis and infection monitoring."
                    ]
                },
                {
                    "protocolName": "KRd (Carfilzomib + Lenalidomide + Dexamethasone)",
                    "drugs": [
                        {
                            "day": "Days 1, 2, 8, 9, 15, 16",
                            "name": "Carfilzomib",
                            "dose": "20 mg/m² → 36–56 mg/m²",
                            "route": "IV",
                            "duration": "30 minutes"
                        },
                        {
                            "day": "Days 1–21",
                            "name": "Lenalidomide",
                            "dose": "25 mg daily",
                            "route": "PO",
                            "duration": "Daily × 21 days"
                        },
                        {
                            "day": "Weekly",
                            "name": "Dexamethasone",
                            "dose": "40 mg",
                            "route": "PO/IV",
                            "duration": "Weekly"
                        }
                    ],
                    "nursingTips": [
                        "Monitor for hypertension and cardiac events—carfilzomib increases risk.",
                        "Ensure hydration pre- and post-infusion.",
                        "Avoid in uncontrolled cardiac conditions."
                    ]
                }
            ]
        },

        "Consolidation Therapy": {
            "goal": "To deepen response after induction or following autologous stem-cell transplantation.",
            "protocols": [
                {
                    "protocolName": "Post-Transplant VRd × 2–4 cycles",
                    "drugs": [
                        { "day": "1, 4, 8, 11", "name": "Bortezomib", "dose": "1.3 mg/m²", "route": "SC", "duration": "Bolus" },
                        { "day": "1–14", "name": "Lenalidomide", "dose": "10–15 mg", "route": "PO", "duration": "Daily" },
                        { "day": "1, 8, 15", "name": "Dexamethasone", "dose": "20–40 mg", "route": "PO/IV", "duration": "Weekly" }
                    ],
                    "nursingTips": [
                        "Often used for high-risk cytogenetics.",
                        "Continue antiviral prophylaxis with bortezomib.",
                        "Monitor neuropathy and blood counts."
                    ]
                },
                {
                    "protocolName": "KRd Consolidation",
                    "drugs": [
                        { "day": "1, 2, 8, 9, 15, 16", "name": "Carfilzomib", "dose": "36–56 mg/m²", "route": "IV", "duration": "30 minutes" },
                        { "day": "1–21", "name": "Lenalidomide", "dose": "10–15 mg", "route": "PO", "duration": "Daily" },
                        { "day": "Weekly", "name": "Dexamethasone", "dose": "20–40 mg", "route": "PO/IV", "duration": "Weekly" }
                    ],
                    "nursingTips": [
                        "Used especially in high-risk cytogenetics (del17p, t(4;14)).",
                        "Monitor BP and cardiac status during carfilzomib."
                    ]
                }
            ]
        },

        "Maintenance Therapy": {
            "goal": "To prolong progression-free survival and maintain remission after induction or transplant.",
            "protocols": [
                {
                    "protocolName": "Lenalidomide Maintenance",
                    "drugs": [
                        {
                            "day": "Days 1–21 of each 28-day cycle",
                            "name": "Lenalidomide",
                            "dose": "10 mg",
                            "route": "PO",
                            "duration": "Daily × 21 days"
                        }
                    ],
                    "nursingTips": [
                        "Monitor for cytopenias every cycle.",
                        "Assess thrombosis risk → consider aspirin prophylaxis.",
                        "Watch for fatigue and secondary malignancy risk."
                    ]
                },
                {
                    "protocolName": "Bortezomib Maintenance (High-Risk)",
                    "drugs": [
                        {
                            "day": "Every 2 weeks",
                            "name": "Bortezomib",
                            "dose": "1.3 mg/m²",
                            "route": "SC",
                            "duration": "Bolus"
                        }
                    ],
                    "nursingTips": [
                        "Preferred for high-risk cytogenetics (del17p, t(4;14)).",
                        "Monitor for neuropathy and shingles reactivation.",
                        "Continue antiviral prophylaxis."
                    ]
                }
            ]
        },

        "Relapsed/Refractory Therapy": {
            "goal": "To regain disease control after progression and improve survival.",
            "protocols": [
                {
                    "protocolName": "Daratumumab (Mono or Combo)",
                    "drugs": [
                        { "day": "Weekly × 8 then spaced", "name": "Daratumumab", "dose": "16 mg/kg IV or 1,800 mg SC", "route": "IV/SC", "duration": "As per schedule" }
                    ],
                    "nursingTips": [
                        "Premedicate with steroid, antihistamine, antipyretic.",
                        "Monitor for infusion reactions—most occur with first dose.",
                        "Ensure blood bank aware: daratumumab interferes with crossmatching."
                    ]
                },
                {
                    "protocolName": "Carfilzomib + Dexamethasone (Kd)",
                    "drugs": [
                        { "day": "1, 2, 8, 9, 15, 16", "name": "Carfilzomib", "dose": "56–70 mg/m²", "route": "IV","duration": "30 minutes" },
                        { "day": "Weekly", "name": "Dexamethasone", "dose": "40 mg", "route": "PO/IV", "duration": "Weekly" }
                    ],
                    "nursingTips": [
                        "Monitor for cardiac failure, hypertension, and dyspnea.",
                        "Hydrate before infusion but avoid fluid overload."
                    ]
                },
                {
                    "protocolName": "Pomalidomide + Dexamethasone",
                    "drugs": [
                        { "day": "Days 1–21", "name": "Pomalidomide", "dose": "4 mg", "route": "PO", "duration": "Daily" },
                        { "day": "Weekly", "name": "Dexamethasone", "dose": "20–40 mg", "route": "PO/IV", "duration": "Weekly" }
                    ],
                    "nursingTips": [
                        "Monitor cytopenias—pomalidomide causes severe neutropenia.",
                        "Thrombosis prophylaxis required.",
                        "Watch for infection and fatigue."
                    ]
                },
                {
                    "protocolName": "Teclistamab (Bispecific Antibody)",
                    "drugs": [
                        { "day": "Dose escalation then weekly", "name": "Teclistamab", "dose": "Step-up dosing", "route": "SC", "duration": "Weekly" }
                    ],
                    "nursingTips": [
                        "Monitor for CRS (cytokine release syndrome) — fever, hypotension.",
                        "Monitor for ICANS (neurotoxicity).",
                        "Hospital admission recommended during initial step-up dosing."
                    ]
                }
            ]
        }
    },

    "HL": {
        "First-Line Therapy": {
            "goal": "To achieve complete remission using combination chemotherapy with or without radiotherapy.",
            "protocols": [
                {
                    "protocolName": "ABVD (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine)",
                    "drugs": [
                        {
                            "day": "Day 1 & 15 (28-day cycle)",
                            "name": "Doxorubicin (Adriamycin)",
                            "dose": "25 mg/m²",
                            "route": "IV",
                            "duration": "Bolus"
                        },
                        {
                            "day": "Day 1 & 15",
                            "name": "Bleomycin",
                            "dose": "10 units/m²",
                            "route": "IV",
                            "duration": "Slow push / short infusion"
                        },
                        {
                            "day": "Day 1 & 15",
                            "name": "Vinblastine",
                            "dose": "6 mg/m²",
                            "route": "IV",
                            "duration": "Bolus"
                        },
                        {
                            "day": "Day 1 & 15",
                            "name": "Dacarbazine",
                            "dose": "375 mg/m²",
                            "route": "IV",
                            "duration": "30–60 min"
                        }
                    ],
                    "nursingTips": [
                        "Monitor pulmonary function – bleomycin is associated with lung toxicity.",
                        "Avoid giving supplemental oxygen unless necessary.",
                        "Anthracycline (doxorubicin) may cause cardiotoxicity – check baseline EF.",
                        "Use central access due to vesicant risk (vinblastine, doxorubicin)."
                    ]
                },
                {
                    "protocolName": "Brentuximab + AVD (ECHELON-1 regimen)",
                    "drugs": [
                        {
                            "day": "Day 1 & 15",
                            "name": "Brentuximab Vedotin",
                            "dose": "1.2 mg/kg",
                            "route": "IV",
                            "duration": "30 min"
                        },
                        {
                            "day": "Day 1 & 15",
                            "name": "Doxorubicin",
                            "dose": "25 mg/m²",
                            "route": "IV",
                            "duration": "Bolus"
                        },
                        {
                            "day": "Day 1 & 15",
                            "name": "Vinblastine",
                            "dose": "6 mg/m²",
                            "route": "IV",
                            "duration": "Bolus"
                        },
                        {
                            "day": "Day 1 & 15",
                            "name": "Dacarbazine",
                            "dose": "375 mg/m²",
                            "route": "IV",
                            "duration": "30–60 min"
                        }
                    ],
                    "nursingTips": [
                        "Brentuximab may cause peripheral neuropathy – monitor closely.",
                        "Avoid bleomycin when giving Brentuximab.",
                        "Premedicate as per protocol to reduce infusion reactions.",
                        "Monitor liver enzymes and CBC every cycle."
                    ]
                }
            ]
        },

        "Second-Line / Salvage Therapy": {
            "goal": "To achieve remission in relapsed or refractory disease and prepare for autologous stem-cell transplant (ASCT).",
            "protocols": [
                {
                    "protocolName": "ICE (Ifosfamide + Carboplatin + Etoposide)",
                    "drugs": [
                        {
                            "day": "Days 1–3",
                            "name": "Ifosfamide + Mesna",
                            "dose": "5 g/m² total",
                            "route": "IV",
                            "duration": "Continuous or fractionated"
                        },
                        {
                            "day": "Day 2",
                            "name": "Carboplatin",
                            "dose": "AUC 5",
                            "route": "IV",
                            "duration": "60 min"
                        },
                        {
                            "day": "Days 1–3",
                            "name": "Etoposide",
                            "dose": "100 mg/m²/day",
                            "route": "IV",
                            "duration": "60 min"
                        }
                    ],
                    "nursingTips": [
                        "Mesna must be given with ifosfamide to prevent hemorrhagic cystitis.",
                        "Ensure daily urinalysis for hematuria on ifosfamide.",
                        "Monitor nephrotoxicity and electrolytes (carboplatin).",
                        "High risk of neutropenia – G-CSF support recommended."
                    ]
                },
                {
                    "protocolName": "GDP (Gemcitabine + Dexamethasone + Cisplatin)",
                    "drugs": [
                        {
                            "day": "Days 1 & 8",
                            "name": "Gemcitabine",
                            "dose": "1000 mg/m²",
                            "route": "IV",
                            "duration": "30 min"
                        },
                        {
                            "day": "Days 1–4",
                            "name": "Dexamethasone",
                            "dose": "40 mg",
                            "route": "PO/IV",
                            "duration": "Daily × 4 days"
                        },
                        {
                            "day": "Day 1",
                            "name": "Cisplatin",
                            "dose": "75 mg/m²",
                            "route": "IV",
                            "duration": "Continuous or split dosing"
                        }
                    ],
                    "nursingTips": [
                        "Hydrate before and after cisplatin to reduce kidney injury.",
                        "Monitor for ototoxicity and neuropathy.",
                        "Gemcitabine may cause thrombocytopenia—check CBC before each dose.",
                        "Encourage good oral hydration throughout treatment."
                    ]
                }
            ]
        },

        "Maintenance / Post-Transplant": {
            "goal": "To prolong remission after autologous stem-cell transplantation.",
            "protocols": [
                {
                    "protocolName": "Brentuximab Maintenance",
                    "drugs": [
                        {
                            "day": "Every 3 weeks",
                            "name": "Brentuximab Vedotin",
                            "dose": "1.8 mg/kg",
                            "route": "IV",
                            "duration": "30 minutes"
                        }
                    ],
                    "nursingTips": [
                        "Preferred in high-risk relapsed HL post-ASCT.",
                        "Monitor neuropathy and liver function each cycle.",
                        "Premedicate if prior infusion reactions occurred."
                    ]
                }
            ]
        }
    },

    "NHL": {
        "First-Line Therapy": {
            "goal": "To achieve remission using subtype-specific chemotherapy and targeted agents.",
            "protocols": [
                {
                    "protocolName": "R-CHOP (DLBCL Standard)",
                    "drugs": [
                        {
                            "day": "Day 1",
                            "name": "Rituximab",
                            "dose": "375 mg/m²",
                            "route": "IV",
                            "duration": "Varies (slow initial titration)"
                        },
                        {
                            "day": "Day 1",
                            "name": "Cyclophosphamide",
                            "dose": "750 mg/m²",
                            "route": "IV",
                            "duration": "30–60 min"
                        },
                        {
                            "day": "Day 1",
                            "name": "Doxorubicin",
                            "dose": "50 mg/m²",
                            "route": "IV",
                            "duration": "Bolus"
                        },
                        {
                            "day": "Day 1",
                            "name": "Vincristine",
                            "dose": "1.4 mg/m² (max 2 mg)",
                            "route": "IV",
                            "duration": "Bolus"
                        },
                        {
                            "day": "Days 1–5",
                            "name": "Prednisone",
                            "dose": "100 mg/day",
                            "route": "PO",
                            "duration": "5 days"
                        }
                    ],
                    "nursingTips": [
                        "Pre-medicate before Rituximab (acetaminophen + antihistamine).",
                        "Monitor closely during first Rituximab infusion for infusion reactions.",
                        "Vincristine is a vesicant—avoid extravasation and NEVER give intrathecally.",
                        "Check cardiac function before doxorubicin (anthracycline)."
                    ]
                },
                {
                    "protocolName": "R-EPOCH (DLBCL, high-risk or double-hit)",
                    "drugs": [
                        {
                            "day": "Day 1",
                            "name": "Rituximab",
                            "dose": "375 mg/m²",
                            "route": "IV",
                            "duration": "Slow titrated infusion"
                        },
                        {
                            "day": "Days 1–4",
                            "name": "Etoposide",
                            "dose": "50 mg/m²/day",
                            "route": "IV",
                            "duration": "Continuous infusion"
                        },
                        {
                            "day": "Days 1–4",
                            "name": "Doxorubicin",
                            "dose": "10 mg/m²/day",
                            "route": "IV",
                            "duration": "Continuous infusion"
                        },
                        {
                            "day": "Days 1–4",
                            "name": "Vincristine",
                            "dose": "0.4 mg/m²/day",
                            "route": "IV",
                            "duration": "Continuous infusion"
                        },
                        {
                            "day": "Day 5",
                            "name": "Cyclophosphamide",
                            "dose": "750 mg/m²",
                            "route": "IV",
                            "duration": "60 min"
                        },
                        {
                            "day": "Days 1–5",
                            "name": "Prednisone",
                            "dose": "60 mg/m²/day",
                            "route": "PO",
                            "duration": "5 days"
                        }
                    ],
                    "nursingTips": [
                        "Requires central line—multiple continuous infusions.",
                        "Vincristine/doxorubicin/etoposide in same CVC lumen for continuous infusion.",
                        "Monitor tumor lysis risk in high-grade lymphomas.",
                        "Daily CBC monitoring due to high risk of cytopenias."
                    ]
                },
                {
                    "protocolName": "Bendamustine + Rituximab (BR) — Follicular / Indolent NHL",
                    "drugs": [
                        {
                            "day": "Day 1",
                            "name": "Rituximab",
                            "dose": "375 mg/m²",
                            "route": "IV",
                            "duration": "Slow initial infusion"
                        },
                        {
                            "day": "Days 1–2",
                            "name": "Bendamustine",
                            "dose": "90 mg/m²/day",
                            "route": "IV",
                            "duration": "30–60 min"
                        }
                    ],
                    "nursingTips": [
                        "Give antiviral prophylaxis (risk of HBV and viral reactivation).",
                        "Infusion reactions possible with Rituximab—observe closely.",
                        "High risk of lymphopenia—monitor for infections.",
                        "Ensure good hydration to prevent nausea and headaches."
                    ]
                }
            ]
        },

        "Second-Line / Relapsed Therapy": {
            "goal": "To achieve disease control or remission and prepare eligible patients for transplant.",
            "protocols": [
                {
                    "protocolName": "DHAP (Dexamethasone + High-Dose Cytarabine + Cisplatin)",
                    "drugs": [
                        {
                            "day": "Days 1–4",
                            "name": "Dexamethasone",
                            "dose": "40 mg/day",
                            "route": "IV/PO",
                            "duration": "4 days"
                        },
                        {
                            "day": "Day 1",
                            "name": "Cisplatin",
                            "dose": "100 mg/m²",
                            "route": "IV",
                            "duration": "24-hour continuous infusion"
                        },
                        {
                            "day": "Day 2",
                            "name": "Cytarabine",
                            "dose": "2 g/m² × 2 doses",
                            "route": "IV",
                            "duration": "3-hour infusion each"
                        }
                    ],
                    "nursingTips": [
                        "Hydrate aggressively with cisplatin—monitor renal function.",
                        "Check neuro signs before each high-dose cytarabine dose.",
                        "High nausea risk—use triple antiemetic prophylaxis.",
                        "Monitor electrolytes during cisplatin infusion."
                    ]
                },
                {
                    "protocolName": "R-GDP (Rituximab + Gemcitabine + Dexamethasone + Cisplatin)",
                    "drugs": [
                        {
                            "day": "Day 1",
                            "name": "Rituximab",
                            "dose": "375 mg/m²",
                            "route": "IV",
                            "duration": "Slow titrated infusion"
                        },
                        {
                            "day": "Days 1 & 8",
                            "name": "Gemcitabine",
                            "dose": "1000 mg/m²",
                            "route": "IV",
                            "duration": "30 min"
                        },
                        {
                            "day": "Days 1–4",
                            "name": "Dexamethasone",
                            "dose": "40 mg/day",
                            "route": "PO/IV",
                            "duration": "4 days"
                        },
                        {
                            "day": "Day 1 or 2",
                            "name": "Cisplatin",
                            "dose": "75 mg/m²",
                            "route": "IV",
                            "duration": "Varies"
                        }
                    ],
                    "nursingTips": [
                        "Check CBC before each gemcitabine dose—risk of thrombocytopenia.",
                        "Monitor for cisplatin nephrotoxicity.",
                        "Premedicate before Rituximab.",
                        "Use adequate hydration to prevent nausea and renal injury."
                    ]
                }
            ]
        },

        "Maintenance Therapy": {
            "goal": "To prolong remission, especially in follicular and indolent lymphomas.",
            "protocols": [
                {
                    "protocolName": "Rituximab Maintenance",
                    "drugs": [
                        {
                            "day": "Every 2–3 months",
                            "name": "Rituximab",
                            "dose": "375 mg/m²",
                            "route": "IV",
                            "duration": "Titrated infusion"
                        }
                    ],
                    "nursingTips": [
                        "Used after BR or R-CHOP in follicular lymphoma.",
                        "Monitor for infusion reactions throughout therapy.",
                        "Assess immunoglobulin levels periodically (risk of hypogammaglobulinemia).",
                        "Screen for HBV before initiation and during therapy."
                    ]
                }
            ]
        }
    },

    "MDS": {
        "Supportive & Symptom-Directed Therapy": {
            "goal": "To improve quality of life, correct cytopenias, and reduce transfusion dependency.",
            "protocols": [
                {
                    "protocolName": "Erythropoietin-Stimulating Agents (ESA)",
                    "drugs": [
                        {
                            "day": "Weekly / Q2 weeks",
                            "name": "Erythropoietin (EPO)",
                            "dose": "40,000–60,000 units",
                            "route": "SC",
                            "duration": "Once weekly or every 2 weeks"
                        },
                        {
                            "day": "Weekly",
                            "name": "Darbepoetin",
                            "dose": "150–300 mcg",
                            "route": "SC",
                            "duration": "Weekly"
                        }
                    ],
                    "nursingTips": [
                        "Monitor CBC every 2–4 weeks to assess response.",
                        "Used mainly for lower-risk MDS with anemia.",
                        "Avoid ESA if Hgb > 12 g/dL due to thrombotic risk.",
                        "Check iron studies and replace iron if low."
                    ]
                },
                {
                    "protocolName": "Luspatercept (for ring sideroblast MDS)",
                    "drugs": [
                        {
                            "day": "Every 3 weeks",
                            "name": "Luspatercept",
                            "dose": "1 mg/kg (titrate to 1.75 mg/kg)",
                            "route": "SC",
                            "duration": "Q3 weeks"
                        }
                    ],
                    "nursingTips": [
                        "Used in lower-risk MDS with ring sideroblasts or SF3B1 mutation.",
                        "Monitor for hypertension and injection-site reactions.",
                        "Assess transfusion needs to evaluate response."
                    ]
                }
            ]
        },

        "Disease-Modifying Therapy (Intermediate / High-Risk)": {
            "goal": "To reduce blast progression, delay evolution to AML, and improve survival.",
            "protocols": [
                {
                    "protocolName": "Azacitidine (AZA)",
                    "drugs": [
                        {
                            "day": "Days 1–7",
                            "name": "Azacitidine",
                            "dose": "75 mg/m²/day",
                            "route": "SC or IV",
                            "duration": "Once daily"
                        }
                    ],
                    "nursingTips": [
                        "This is the most standard first-line therapy for high-risk MDS.",
                        "Responses may take 4–6 cycles—continue unless clear progression.",
                        "Monitor for cytopenias; dose delays are common.",
                        "Premedicate for nausea; SC injections may cause local irritation."
                    ]
                },
                {
                    "protocolName": "Decitabine",
                    "drugs": [
                        {
                            "day": "Days 1–5",
                            "name": "Decitabine",
                            "dose": "20 mg/m²/day",
                            "route": "IV",
                            "duration": "1 hour infusion"
                        }
                    ],
                    "nursingTips": [
                        "Equivalent alternative to azacitidine for higher-risk MDS.",
                        "Higher risk of neutropenia—monitor CBC closely.",
                        "Antimicrobial prophylaxis is often recommended."
                    ]
                }
            ]
        },

        "High-Risk / TP53-Mutated Disease": {
            "goal": "To control aggressive disease, bridge to transplant, or offer low-intensity treatment for non-transplant candidates.",
            "protocols": [
                {
                    "protocolName": "Azacitidine + Venetoclax",
                    "drugs": [
                        {
                            "day": "Days 1–7",
                            "name": "Azacitidine",
                            "dose": "75 mg/m²/day",
                            "route": "SC or IV",
                            "duration": "Daily"
                        },
                        {
                            "day": "Days 1–14 or 1–21",
                            "name": "Venetoclax",
                            "dose": "100–400 mg/day (ramp-up)",
                            "route": "PO",
                            "duration": "Daily with ramp-up"
                        }
                    ],
                    "nursingTips": [
                        "Monitor for tumor lysis syndrome—especially first cycle.",
                        "Significant neutropenia risk—expect antimicrobial prophylaxis.",
                        "Used for very high-risk, TP53-mutated, or AML-evolving MDS."
                    ]
                },
                {
                    "protocolName": "CPX-351 (for AML-transformed MDS)",
                    "drugs": [
                        {
                            "day": "Days 1, 3, 5",
                            "name": "CPX-351 (Vyxeos)",
                            "dose": "44 mg/m² daunorubicin + 100 mg/m² cytarabine",
                            "route": "IV",
                            "duration": "90 min infusion"
                        }
                    ],
                    "nursingTips": [
                        "Used when MDS evolves to AML or in therapy-related MDS.",
                        "Expect prolonged cytopenias—supportive care essential.",
                        "Central line required; premedicate to prevent infusion reactions."
                    ]
                }
            ]
        }
    }

}
